Article Text

Download PDFPDF

Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
  1. Alexis Jones1,
  2. Patrick Muller2,
  3. Caroline J Dore2,
  4. Felicia Ikeji2,
  5. Emilia Caverly2,
  6. Kashfia Chowdhury2,
  7. David A Isenberg1,
  8. Caroline Gordon3,
  9. Michael R Ehrenstein1
  1. 1 Centre for Rheumatology, Division of Medicine, University College London, London, UK
  2. 2 Comprehensive Clinical Trials Unit, University College London, London, UK
  3. 3 Rheumatology Research Team - Inflammation and Ageing (IIA), University of Birmingham Research Laboratories, New Queen Elizabeth Hospital, Birmingham, UK
  1. Correspondence to Professor Michael R Ehrenstein; m.ehrenstein{at}ucl.ac.uk

Abstract

Introduction Few treatment options exist for patients with systemic lupus erythematosus (SLE) who fail conventional therapy. Although widely used to treat lupus, the efficacy of B cell depletion therapy using rituximab has not been demonstrated in randomised clinical trials. Following rituximab, elevated levels of serum B cell activating factor (BAFF) have been associated with failure to remit or subsequent lupus relapse. The administration of belimumab, a monoclonal antibody specific for BAFF and approved for lupus therapy, could potentiate the efficacy of rituximab and enable longer periods of disease remission. The aim of this trial is to assess the safety and efficacy of belimumab following rituximab in patients with SLE.

Methods and analysis BEAT Lupus is a double-blind, randomised, placebo controlled, phase II clinical trial. Patients with SLE commencing a treatment cycle of rituximab (two 1g infusions, 2 weeks apart) as standard of care will be randomised to receive belimumab or placebo, 4 to 8 weeks following the first rituximab infusion. Belimumab or placebo infusions are administered for 52 weeks. The primary outcome measure is anti-double stranded DNA (anti-dsDNA) antibody levels at 52 weeks. Secondary outcomes include measures of adverse events, lupus disease activity and cumulative steroid dose. The kinetics of B cell repopulation will be assessed in a subgroup of participants. Belimumab administration after rituximab may provide a novel therapeutic pathway for patients with active lupus if safety is demonstrated in this proof of concept study, and lower anti-dsDNA antibodies levels are achieved in those patients treated with belimumab compared with placebo.

Ethics and dissemination The protocol has been reviewed and approved by the Hampstead Research Ethics Committee - London (reference 16/LO/1024). Trial information is available at https://www.isrctn.com/ISRCTN47873003, and the results of this trial will be submitted for publication in relevant peer-reviewed journals. Key findings will also be presented at national and international conferences.

Trial registration number ISRCTN47873; date assigned to the registry: 28 November 2016. The stage is pre-results.

  • rheumatology
  • rheumatology
  • immunology

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors MRE conceived of the study. MRE, CG, CJD and DAI initiated the study design. PM and KC and CJD provided statistical expertise in clinical trial in clinical trial design. MRE, CG, CJD, FI and EC assisted with protocol development. MRE, DAI, CG and CJD are grant holders.

  • Funding This trial is supported by Versus Arthritis (grant number 20873) and the UCLH Biomedical Research Centre (BRC). GSK are providing belimumab free of charge, as well as additional funding. The MRC (MASTERPLANS CONSORTIUM) is supporting some of the experimental medicine applied to samples from this trial. GSK had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data or decision to submit results. Versus Arthritis and the MRC reviewed the relevant grant proposals and monitor progress of relevant aspects of the study but will not play any role in the analyses, interpretation of data or decision to submit results.

  • Competing interests MRE has received grant/research support from GSK. CG has been a member of the speakers bureau for GSK and has received consultancy fees for attending advisory boards.

  • Patient consent for publication Not required.

  • Ethics approval London - Hampstead Research Ethics Committee REC reference: 16/LO/1024, Health Research Authority IRAS project ID: 195085, EudraCT number: 2015-005543-14.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.